A tin pot dictator plunders billions from his blighted nation’s treasury. Sensing he’ll soon be exiled, amid public relations fanfare, he offers ill-gotten millions to a local university for a new school…
Rigor acadêmico, estilo jornalístico
Todos os artigos de Pharmaceuticals
Exibindo 121 - 140 de 203 artigos
About 8% of the population is unable to metabolise codeine, and a small number metabolise it at a much larger extent.
What will happen to immigration, wages and the economy has been discussed at length. But the price of drugs may also be affected.
After years of complaints, will the British Army now use controversial anti-malarial as a drug of last resort?
Many suspect Van Gogh suffered from foxglove extract overdose due to the yellow halos in his paintings and his portrait of his physician holding the plant.
How new medicines subsidised by individual nations in the EU is a complicated business.
Good models have been developed to ensure benefit sharing in the biodiversity business. But major challenges prevent developing countries from translating this into social justice.
Drugs, new materials and even more creative uses: biodiversity is full of potential.
Some advertising content bypasses regulations to promote unrealistic beliefs about drugs.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
More than 700,000 people die each year from antibiotic-resistant infections. The World Health Organisation is trying to end the age of ignorance to protect this global common good.
We need new ways to pay drug producers if we are to make treatments available where they’re really needed.
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
This project offers the tantalising possibility that plants containing drugs, such as agents to treat HIV, could be farmed on a small scale at low cost by communities that need them most.
Clinton, who named drug companies among her enemies in this week’s debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
News that a leading manufacturer will cease making a well-known antivenom is not actually new.
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
The generic drug industry has become essential to developing countries that need access to cheaper drugs to treat their heavy burdens of communicable diseases.
Biologics are widely accepted as the most effective way of treating certain diseases. They have become the fastest-growing class of therapeutic compounds, with about 300 now available for human use.
Combination drugs are considered an innovation of India’s medicines industry but they are not as safe as they should be.
Principais colaboradores
-
Professor and Director Academic Excellence, Macquarie University
-
Joel Lexchin é um amigo do The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Lecturer Pharmacy Practice, University of Sydney
-
Pharmacist and PhD Candidate, University of Sydney
-
HERA Program Director - Health Workforce Optimisation Centre for the Business & Economics of Health, The University of Queensland
-
Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Research associate, University of Pretoria
-
Research Fellow, Stellenbosch University
-
Lecturer in Accounting & Management, Lancaster University
-
ARC Future Fellow, Australian National University
-
Purple House Medical Advisor. Honorary ANU., Australian National University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics, Macquarie University
